Duncan Energy Partners LP
http://www.deplp.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Duncan Energy Partners LP
Mabwell’s Denosumab Biosimilar Shows Similar Efficacy To Xgeva
Mabwell’s denosumab biosimilar MW032, which awaits approval in China, achieved similar efficacy and safety profiles as the originator Xgeva in oncology patients.
What will become of the German antidiabetics market?
Yet another company – this time Novo Nordisk – has decided that it wouldn't be good business to sell its antidiabetic in Germany following a rocky ride through the AMNOG benefit assessment and pricing negotiations. While companies are worried about the future of treatments for chronic diseases in Germany, prescribers and health insurers are more sanguine and believe that German patients are not yet missing out on important innovations in the market.
Aegerion sinks on 3Q Juxtapid sales, forecast
Aegerion Pharmaceuticals sank 41% to $20.19 per share on 31 October after the company revealed lower than expected third quarter sales and cut its full-year 2014 sales guidance due to increased discontinuation rates for Juxtapid (lomitapide) and reimbursement challenges in ex-US markets.
Germany's IQWiG verdict for Sovaldi sets scene for tough pricing negotiations
Gilead's Sovaldi (sofosbuvir) provides additional benefit in hepatitis C virus (HCV) patients, but that benefit is unquantifiable, according to Germany's health technology appraisal body, IQWiG. The institute's lukewarm evaluation sets the scene for difficult pricing negotiations for Gilead.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice